Vaccine (mRNA vaccine) · Immune activation, directed at HPV-16 E6 oncoprotein and HPV-16 E7 oncoprotein · developed by BioNTech
BNT113 is an RNA-lipoplex cancer vaccine containing messenger RNA encoding the human papillomavirus type 16 E6 and E7 oncoproteins, encapsulated in liposomes. After uptake by antigen-presenting cells, the expressed antigens are presented to the immune system to induce CD8+ and CD4+ T-cell responses against HPV16 E6 and E7, and it is studied in HPV16-positive head and neck squamous cell carcinoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04534205 | Phase 2/3 | Unresectable Head and Neck Squamous Cell Carcinoma | Active not recruiting | BNTX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Metastatic Head and Neck CancerRecurrent Head and Neck CancerUnresectable Head and Neck Squamous Cell Carcinoma
See BNTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
BNTX catalysts and pipeline →